dr. (Margreet) M.G. Franken

(external) researcher Erasmus School of Health Policy & Management Health Technology Assessment (HTA)

Location: Erasmus University Rotterdam
Room: J 8-23
Telephone: +31 10 4081372
Email: franken@eshpm.eur.nl

Profile

Margreet Franken obtained a Bachelor degree in Nursing and a Master degree in Health Economics, Policy and Law. From 1992 until 2008 she worked as a quality care manager, clinical nurse educator, and specialised coronary and intensive care nurse in hospitals in Arnhem, Rotterdam and Christchurch (New Zealand). Since 2008, Margreet has been working as a researcher at the institute of Health Policy and Management at the Erasmus University in Rotterdam. Her research interests include outcomes research of expensive drugs and drug reimbursement. Currently, she works on the Escher project of the Dutch Top Institute Pharma (TIPharma) towards her PhD focusing on drug reimbursement systems and reimbursement criteria.

- H.Y. Tan, M.G. Franken, H.M. Blommestein, C.A. Uyl - de Groot & P. Sonneveld (2017). Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. Journal of Clinical Oncology, 35 (12), 1312-+. doi: 10.1200/jco.2016.71.1663
- M.G. Franken, E. Heintz, A. Gerber-Grote & J. Raftery (2016). Health Economics as Rhetoric: The Limited Impact of Health Economics on Funding Decisions in Four European Countries. Value in Health, 19 (8), 951-956. doi: http://dx.doi.org/10.1016/j.jval.2016.08.001[go to publisher's site]
- M.G. Franken (2014, december 5). Decision Making in Drug Reimbursement. EUR (266 pag.) Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & A. de Boer.
- M.G. Franken, J.G. Gaultney, H.M. Blommestein, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2014). Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Value in Health, 17, 245-253. doi: http://dx.doi.org/10.1016/j.jval.2013.12.009[go to publisher's site]
- M.G. Franken, M.A. Koopmanschap & A. Steenhoek (2014). Health economic evaluations in reimbursement decision making in the Netherlands: Time to take it seriously? Elsevier, 108 (7), 383-389. doi: 10.1016/j.zefq.2014.06.016[go to publisher's site]
- M.G. Franken, F. Nilsson, F.G. Sandmann, A. de Boer & M.A. Koopmanschap (2013). Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. Pharmacoeconomics (Print), 31 (9), 781-797. doi: http://dx.doi.org/10.1007/s40273-013-0074-1[go to publisher's site]
- M.G. Franken, C.W.M. van Gils, J.G. Gaultney, G. Delwel, W. Goettsch, P.C. Huijgens, A. Steenhoek, C.J.A. Punt, M. Koopman, W.K. Redekop & C.A. de Uyl-de Groot (2013). Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands. European Journal of Cancer, 49, 8-16. doi: http://dx.doi.org/10.1016/j.ejca.2012.06.010[go to publisher's site]
- - H.Y. Tan, M.G. Franken, H.M. Blommestein, C.A. Uyl - de Groot & P. Sonneveld (2017). Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. Journal of Clinical Oncology, 35 (12), 1312-+. doi: 10.1200/jco.2016.71.1663
  - M.G. Franken, E. Heintz, A. Gerber-Grote & J. Raftery (2016). Health Economics as Rhetoric: The Limited Impact of Health Economics on Funding Decisions in Four European Countries. Value in Health, 19 (8), 951-956. doi: http://dx.doi.org/10.1016/j.jval.2016.08.001[go to publisher's site]
  - M.G. Franken (2014, december 5). Decision Making in Drug Reimbursement. EUR (266 pag.) Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & A. de Boer.
  - M.G. Franken, J.G. Gaultney, H.M. Blommestein, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2014). Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Value in Health, 17, 245-253. doi: http://dx.doi.org/10.1016/j.jval.2013.12.009[go to publisher's site]
  - M.G. Franken, M.A. Koopmanschap & A. Steenhoek (2014). Health economic evaluations in reimbursement decision making in the Netherlands: Time to take it seriously? Elsevier, 108 (7), 383-389. doi: 10.1016/j.zefq.2014.06.016[go to publisher's site]
  - M.G. Franken, F. Nilsson, F.G. Sandmann, A. de Boer & M.A. Koopmanschap (2013). Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. Pharmacoeconomics (Print), 31 (9), 781-797. doi: http://dx.doi.org/10.1007/s40273-013-0074-1[go to publisher's site]
  - M.G. Franken, C.W.M. van Gils, J.G. Gaultney, G. Delwel, W. Goettsch, P.C. Huijgens, A. Steenhoek, C.J.A. Punt, M. Koopman, W.K. Redekop & C.A. de Uyl-de Groot (2013). Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands. European Journal of Cancer, 49, 8-16. doi: http://dx.doi.org/10.1016/j.ejca.2012.06.010[go to publisher's site]
- - - A. Jochems, B. Leeneman, M.G. Franken, M.G. Schouwenburg, M. Aarts, A.C.J. van Akkooi, F. van den Berkmortel, A.J.M. Van den Eertwegh, G. Groenewegen, J. de Groot, J. Haanen, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H.J. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, A. ten Tije, G. Vreugdenhil, M.W.J.M. Wouters, C.A. de Groot & J.J.M. van der Hoeven (2018). Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 29 (6), 572-578. doi: 10.1097/CAD.0000000000000629[go to publisher's site]
    - M.G. Schouwenburg, A. Jochems, B. Leeneman, M.G. Franken, A.J.M. Van den Eertwegh, J. Haanen, M. Zeijl, M. Aarts, A.C.J. van Akkooi, F. van den Berkmortel, W.A.M. Blokx, J. de Groot, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H.J. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, K. Suijkerbuijk, A. ten Tije, G. Vreugdenhil, M.W.J.M. Wouters & J.J.M. van der Hoeven (2018). Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. Melanoma Research. doi: 10.1097/CMR.0000000000000453[go to publisher's site]
    - M.G. Franken, I. Corro Ramos, J. Los & M.J. Al (2018). The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios. BMC Family Practice, 19 (31). doi: DOI 10.1186/s12875-018-0714-9[go to publisher's site]
    - M.G. Franken, B. Leeneman, A. Jochems, M.G. Schouwenburg, M. Aarts, A.C.J. van Akkooi, F. van den Berkmortel, A.J.M. Van den Eertwegh, J. de Groot, J.J.M. van der Hoeven, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H.J. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, K. Suijkerbuijk, A. ten Tije, G. Vreugdenhil, M.W.J.M. Wouters, M. Zeijl, J. Haanen & C.A. de Groot (2018). Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 29 (6), 579-588. doi: 10.1097/CAD.0000000000000628[go to publisher's site]
    - H.Y. Tan, M.G. Franken, H.M. Blommestein, C.A. Uyl - de Groot & P. Sonneveld (2017). Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. Journal of Clinical Oncology, 35 (12), 1312-+. doi: 10.1200/jco.2016.71.1663
    - C.H.Y. van Beurden-Tan, M.G. Franken, H.M. Blommestein, C.A. de Uyl-de Groot & P. Sonneveld (2017). Reply to X. Armoiry et al. Journal of Clinical Oncology, 35 (25), 2976. doi: https://doi.org/10.1200/JCO.2017.73.7569
    - A. Jochems, M.G. Schouwenburg, B. Leeneman, M.G. Franken, A.J.M. Van den Eertwegh, J. Haanen, H. Gelderblom, C.A. de Uyl-de Groot, M. Aarts, F. van den Berkmortel, W.A.M. Blokx, M.C. Cardous-Ubbink, G. Groenewegen, J. de Groot, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, A. ten Tije, G. Vreugdenhil, M.W.J.M. Wouters & J.J.M. van der Hoeven (2017). Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. European Journal of Cancer, 72, 156-165. doi: 10.1016/j.ejca.2016.11.021
    - S. de Groot, N. van der Linden, M.G. Franken, H.M. Blommestein, B. Leeneman, E.M. van Rooijen, J.J.M. van der Hoeven, M. Wouters, H.M. Westgeest & C.A. de Uyl-de Groot (2016). Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences. Value in Health. doi: 10.1016/j.jval.2016.02.007[go to publisher's site]
    - M.G. Franken, E. Heintz, A. Gerber-Grote & J. Raftery (2016). Health Economics as Rhetoric: The Limited Impact of Health Economics on Funding Decisions in Four European Countries. Value in Health, 19 (8), 951-956. doi: http://dx.doi.org/10.1016/j.jval.2016.08.001[go to publisher's site]
    - M.G. Franken, E.A. Stolk, T. Scharringhausen, A. de Boer & M.A. Koopmanschap (2015). A comparative study of the role of disease severity in drug reimbursement decision making in four European countries. Health Policy, 119 (2), 195-202. doi: 10.1016/j.healthpol.2014.10.007[go to publisher's site]
    - H.M. Blommestein, M.G. Franken & C.A. de Uyl-de Groot (2015). A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry. Pharmacoeconomics (Print). doi: http://dx.doi.org/10.1007/s40273-015-0260-4[go to publisher's site]
    - J.G. Gaultney, M.G. Franken, C.A. de Uyl-de Groot, W.K. Redekop, P.C. Huijgens, B. van der Holt, H.M. Lokhorst & P. Sonneveld (2015). Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement. Health Policy, 119 (2), 186-194. doi: 10.1016/j.healthpol.2014.11.010[go to publisher's site]
    - H.M. Blommestein, M.G. Franken, S.G.R. Verelst, M. van Agthoven, P.C. Huijgens & C.A. de Uyl-de Groot (2014). Access to expensive cancer drugs in Dutch daily practice: Should we be concerned? Netherlands Journal of Medicine, 72 (4), 235-241. doi: http://dx.doi.org/1765/77541[go to publisher's site]
    - M.G. Franken, J.G. Gaultney, H.M. Blommestein, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2014). Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Value in Health, 17, 245-253. doi: http://dx.doi.org/10.1016/j.jval.2013.12.009[go to publisher's site]
    - M.G. Franken, M.A. Koopmanschap & A. Steenhoek (2014). Health economic evaluations in reimbursement decision making in the Netherlands: Time to take it seriously? Elsevier, 108 (7), 383-389. doi: 10.1016/j.zefq.2014.06.016[go to publisher's site]
    - F.G. Sandmann, M.G. Franken & A. Steenhoek (2013). Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. Health Policy, 112 (3), 285-296. doi: http://dx.doi.org/10.1016/j.healthpol.2013.03.006[go to publisher's site]
    - M.G. Franken, F. Nilsson, F.G. Sandmann, A. de Boer & M.A. Koopmanschap (2013). Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making. Pharmacoeconomics (Print), 31 (9), 781-797. doi: http://dx.doi.org/10.1007/s40273-013-0074-1[go to publisher's site]
    - M.G. Franken & X.H.E. Koolman (2013). Health system goals: A discrete choice experiment to obtain societal valuations. Health Policy, 112 (1-2), 28-34. doi: http://dx.doi.org/10.1016/j.healthpol.2012.12.013[go to publisher's site]
    - J.G. Gaultney, M.G. Franken, S.S. Tan, W.K. Redekop, P.C. Huijgens, P. Sonneveld & C.A. de Uyl-de Groot (2013). Real-world healthcare costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. Journal of Clinical Pharmacy and Therapeutics, 38, 41-47. doi: 10.1111/jcpt.12020
    - M.G. Franken, C.W.M. van Gils, J.G. Gaultney, G. Delwel, W. Goettsch, P.C. Huijgens, A. Steenhoek, C.J.A. Punt, M. Koopman, W.K. Redekop & C.A. de Uyl-de Groot (2013). Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands. European Journal of Cancer, 49, 8-16. doi: http://dx.doi.org/10.1016/j.ejca.2012.06.010[go to publisher's site]
    - M.G. Franken, M. le Polain, I. Cleemput & M.A. Koopmanschap (2012). SIMILARITIES AND DIFFERENCES BETWEEN FIVE EUROPEAN DRUG REIMBURSEMENT SYSTEMS. International Journal of Technology Assessment in Health Care, 28 (4), 349-357. doi: http://dx.doi.org/10.1017/S0266462312000530
    - J.G. Gaultney, M.G. Franken, S.S. Tan, W.K. Redekop, P.C. Huijgens, P. Sonneveld & C.A. de Uyl-de Groot (2012). Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. Journal of Clinical Pharmacy and Therapeutics. doi: http://dx.doi.org/10.1111/jcpt.12020
    - I. Cleemput, M.G. Franken, M.A. Koopmanschap & M. le Polain (2012). EUROPEAN DRUG REIMBURSEMENT SYSTEMS' LEGITIMACY: FIVE-COUNTRY COMPARISON AND POLICY TOOL. International Journal of Technology Assessment in Health Care, 28 (4), 358-366. doi: http://dx.doi.org/10.1017/S0266462312000529
    - S.S. Tan, C.W.M. van Gils, M.G. Franken, L. Hakkaart-van Roijen & C.A. de Uyl-de Groot (2010). The Unit Costs of Inpatient Hospital Days, Outpatient Visits and Daycare Treatments in the Fields of Oncology and Hematology. Value in Health, 13 (6), 712-719. doi: http://dx.doi.org/10.1111/j.1524-4733.2010.00740.x
  - - M.A. Koopmanschap, J.L. Severens & M.G. Franken (2012). Internationale aspecten bij besluitvorming inzake geneesmiddelenvergoeding. Economisch-Statistische Berichten, 97 (4644S), 36-39.
    - A. Steenhoek, M.A. Koopmanschap, M.G. Franken & F.F.H. Rutten (2010). Nieuwe geneesmiddelen: niet goed, geld terug? Nederlands Tijdschrift voor Geneeskunde, 154 (A2042), 1-5.
- - - M. le Polain, M.G. Franken, M.A. Koopmanschap & I. Cleemput (2010). Drug reimbursement systems: international comparison and policy recommendations. (Extern rapport, KCE Reports, no 147C). Brussel: Federaal Kenniscentrum voor de gezondheidszorg - Centre fédéral d'expertise des soins de santé
  - - M.G. Franken, J.G. Gaultney, H.M. Blommestein, S.S. Tan, C.W.M. van Gils, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2012). Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma. (Extern rapport). Rotterdam: Erasmus Universiteit Rotterdam - GE-iMTA
- - M.G. Franken (2014, december 5). Decision Making in Drug Reimbursement. EUR (266 pag.) Prom./coprom.: prof.dr. C.A. de Uyl-de Groot & A. de Boer.
ST. Franciscus Gasthuis
Start Date
Jan/2010
End Date
Is current
Place
ROTTERDAM
Kwaliteit van Zorg
Title
Kwaliteit van Zorg
Year
2018
Period
BLOK4 B1
Year level
bachelor 1 (Gezondheidswetenschappen)
Kwaliteit van Zorg
Title
Kwaliteit van Zorg
Year
2018
Period
BLOK4 B1
Year level
bachelor 1 (Gezondheidswetenschappen)
Kwaliteit van Zorg
Title
Kwaliteit van Zorg
Year
2018
Period
BLOK4 B1
Kwaliteit & Doelmatigheid
Title
Kwaliteit & Doelmatigheid
Year
2018
Period
BLOK5 B2
Year level
bachelor 2 (Gezondheidswetenschappen)
(external) researcher
University
Erasmus University Rotterdam
School
Erasmus School of Health Policy & Management
Department
Health Technology Assessment (HTA)
Country
Nederland
Telephone
+31 10 4081372

Address

Visiting address

Burg. Oudlaan 50 3062 PA Rotterdam

Postal address

Postbus 1738 3000 DR Rotterdam

dr. (Margreet) M.G. Franken

More information

Profile

Featured publications (7)

All publications (36)

Key publication (7)

Article (26)

Scholarly Publication (24)

Professional Publication (2)

Report (2)

Scholarly Publication (1)

Other Publication (1)

Doctoral thesis (1)

Ancillary activities (1)

ST. Franciscus Gasthuis

Teaching (4)

Kwaliteit van Zorg

Kwaliteit van Zorg

Kwaliteit van Zorg

Kwaliteit & Doelmatigheid

Present position

(external) researcher

Address

Visiting address

Postal address